The Global Health Primer Theresa W. Gillespie, PhD, MA, RN Associate Professor, Emory University School of Medicine Director, Strategic Initiatives, Emory Institute for Drug Development Atlanta, Georgia, USA Neglected Tropical Diseases Research & Development

 Numerous reports over decades cited gap in R&D for neglected diseases  Need for increased funding, incentives, & commitment in R&D for neglected diseases, especially for stages of development post- discovery (“valley of death”)  Need for tracking, monitoring, reporting & analyzing R&D for NTD  The Global Health Primer www.globalhealthprimer.org

Emory University & The Emory Institute for Drug Development

 Emory University, Research University located in Atlanta, Georgia (“Global Health Capital of the US”)  School of Medicine (Primate Center, Vaccine Center, Winship Cancer Institute- Ph 1 trials)  Rollins School of Public Health, Dept of Global Health  Goizueta School of Business  Emory Institute for Drug Development – Dennis Liotta, PhD, focus on anti-virals (HIV/AIDS)

The Global Health Primer

 Previously developed and maintained by BIO Ventures for Global Health  2012 – RFA competitive process to transfer Primer to new host  October 2012 Emory University awarded GHP  December 2012 Primer effectively transferred to Emory  Continue same objectives re: tracking R&D and expand with new goals, e.g. education GHP Neglected Diseases *=WHO NTD (17)

 Buruli ulcer*  Lymphatic filariasis*  Chagas disease*  Malaria  Cholera  Onchocerciasis*  Dengue*  Pneumococcal disease  Diarrheal diseases  Rotavirus  Dracunculiasis*  Schistosomiasis*  Enterotoxigenic E. Coli  Shigellosis  Fascioliasis  Soil Transmitted Helminths*  Human African Trypanosomiasis*  Trachoma*  HIV  TB  Leishmaniasis*  Typhoid fever  Leprosy  Yaws* GHP – Current Capabilities www.globalhealthprimer.org  Search by disease  Search by drug targets The Global Health Primer connects the capable innovators that drive research and development for new drugs, vaccines, and diagnostics to the (e.g. kinases) neglected diseases where innovation is desperately needed. It provides a source of compiled and synthesized information for 25 neglected diseases of the developing world and the drugs, vaccines, and diagnostics in use or  Search by technology in development for the management of these diseases. The Global Health Primer: •Tracks and analyzes progress in global health research and (e.g. vaccines) development •Provides an evidence base to support decision making, policy change, and action  Diagnostics •Brings new innovators to the table to address the most pressing medical needs of the poor Since the re-launch of the Global Health Primer in March 2011, BVGH has  Pipeline for each disease, successfully conducted quarterly updates of the report content and significantly expanded the content. In 2012, the Global Health Primer Scientific Advisory Board (SAB) was formed to review all contents of the target, technology Primer, and to ensure the data are scientifically accurate and reliable. BVGH also published an overview of the current pipeline in the Global Health Primer:  Updated via data collection directly from 2012

R&D sources, media, Watch a short demo of the Global Health Primer here: publications

Global Health Primer- Future Goals & Directions

 Expand information/materials available on Primer site to include learning opportunities related to NTD, R&D, Business Development, IP, Policy (ex: South Africa Scholars Program)  Engage students & faculty from Medicine, Public Health, Business, Nursing Schools  Modify data platform to enable more complex analyses & compatibilities with other agencies  Grow collaborations with other groups, locally (Carter Center, Task Force for Global Health, CDC) & across US & abroad  Future: Extend to rare diseases, NCD (cancers)